Physician profile
Eric S Broadway
NPI 1790870905
$10,565.95
in general payments reported to CMS, 2019-2025
21 companies · $1,564 in 2025
The $1,564 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $1,322 · 2021: $1,716 · 2022: $1,680 · 2023: $2,055 · 2024: $1,787 · 2025: $1,564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,195 · Education: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,194.63 |
| Education | $212.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,737.69 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $1,355.07 | 2021-2024 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,275.32 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $1,045.79 | 2019-2025 | Invega Sustenna, Invega, Spravato |
| Neurocrine Biosciences, INC. | $1,027.90 | 2019-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $863.53 | 2020-2022 | |
| Alkermes, INC. | $680.24 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Supernus Pharmaceuticals, INC. | $452.51 | 2021-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $441.91 | 2019-2025 | Rexulti, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $434.11 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $428.68 | 2019-2025 | Fanapt, Hetlioz |
| Allergan, INC. | $382.61 | 2019-2020 | |
| Lundbeck LLC | $142.09 | 2021-2024 | Rexulti |
| Axsome Therapeutics, INC. | $83.42 | 2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $52.33 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $47.69 | 2019-2020 | |
| Eisai INC. | $37.70 | 2020 | |
| Indivior INC. | $26.91 | 2022-2023 | Perseris |
| Pear Therapeutics (US), INC. | $20.97 | 2022 | |
| Adlon Therapeutics L.P. | $14.74 | 2020 | |
| Novo Nordisk INC | $14.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Broadway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.